UpToDate’s Post

FRUQUINTINIB(FRUZAQLA/ELUNATE) is the first targeted therapy approved for metastatic colorectal cancer (mCRC) Regardless of biomarker status or prior types of therapies in more than a decade. FRUQUINTINIB(FRUZAQLA/ELUNATE) plus best supportive care demonstrated significant improvements in overall survival, with corresponding improvements in progression-free survival, versus placebo plus best supportive care in two phase 3 clinical trials. FRUQUINTINIB(FRUZAQLA/ELUNATE) demonstrated a manageable safety profile in previously treated patients with mCRC across both trials.

Finally, adjuvant renal cancer treatment shows OS benefit ✅ by Mariella Attard After decades of negative results in the field, adjuvant pembrolizumab has demonstrated a significant survival benefit for renal cell cancer patients. https://lnkd.in/g3b6utXS #oncology #cancer #pembrolizumab

Learn more about advancements in MSS colorectal cancer treatment from Dr. Daneng Li, who discusses the promising outcomes of our phase 1b/2 study of our masked, anti-CTLA-4 ADG126 in combination with pembrolizumab presented earlier this year. With a favorable safety profile and ~22% ORR, this combo showed potential to significantly widen the therapeutic index for MSS CRC patients and improve survival outcomes. Don't miss Dr. Li's insights on these early outcomes and their significance ahead of more updates at ESMO Congress 2024: https://loom.ly/4FYKRHE #CancerResearch #Immunotherapy #Oncology

Want to learn more about the rationale for renal cell carcinoma (RCC) screening? Watch this EMUC23 webcast presentation by Prof. Grant Stewart (GB), where he shares details of the Wilson & Jungner/WHO screening study checklist, as well as the Yorkshire Kidney Screening Trial. Looking to the future, will an early detection RCC strategy be useful to patients and cost-effective? Find out more here. 👇 #kidneycancer #oncology

Votrient – Treatment for Renal Cell Cancer and Soft Tissue Sarcoma Renal Cell Cancer (RCC) is one of the type of Kidney Cancer which affects the inner lining of the kidney. Renal cancer is generally seen in adult men aged between 50 to 60 years. This type of disease can easily spread to to Lungs and other organs of the body. See Full Article: https://shorturl.at/duDP3 #Votrient #RenalCellCancer #SoftTissueSarcoma #CancerTreatment #Oncology #TargetedTherapy #KidneyCancer #SarcomaAwareness #MedicalTreatment #CancerSupport #Healthcare #CancerResearch #PatientCare #TherapeuticOptions #DrugTherapy #CancerAwareness #TreatmentOptions #OncologyCare #ClinicalTrial #DiseaseManagement

A recent retrospective cohort study (DOI: 10.1245/s10434-024-15314-9) delves into initial tumor reduction (ITR) as a decisive prognostic marker in esophageal squamous cell cancer treatment 🏥🔍. Tracking 150 patients, the study established that an ITR ≥10% correlates with enhanced survival and treatment efficacy post-chemotherapy 📈. The findings suggest incorporating ITR measurement in clinical evaluations to refine ESCC treatment strategies, marking a step forward in precision oncology and personalized healthcare 🧬🎗️. #MedicalResearch #EsophagealCancer #PersonalizedMedicine #OncologyInnovation

Insightful article shared by Clarivate for Life Sciences & Healthcare Oncology team published in Nature Drug Discovery!! Our authors mention in the article "Between 2023 and 2032, the market will become increasingly crowded, with novel drugs expected to gain approval." Click below to read more. #Clarivateoncology #oncology #targetedtherapy #HER2positive #triplenegative

Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available - Earle Burgess #Cancer #BladderCancer #CancerCare #Enfortumab #GenitourinaryOncology #OncoDaily #Oncology #ProstateCancer

Our metaanaylsis published today: Our meta-analysis delves into the safety and efficacy of polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in treating BRCA-mutated breast cancer. After analyzing six randomized control trials with 3610 patients, we found that PARPi therapy significantly improves progression-free survival (HR: 0.64) and overall survival (HR: 0.84) compared to standard chemotherapy or placebo. Importantly, while PARPi increases the risk of anemia (RR: 6.17), it does not heighten the risk of other adverse events. Bravo to Zaheer Qureshi and team! Remember, true success is always a collective achievement. Read the full article here: [Efficacy and Safety of BRCA-targeted Therapy](https://lnkd.in/gbWf2j5M) #breastcancer #BRCA #PARPinhibitors #oncology #clinicalresearch #systematicreview #metaanalysis

🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗨 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 In our latest episode, Prof Emmanuel Seront and Prof Christof Vulsteke provide a detailed analysis of the KEYNOTE-B61 study, a significant leap forward in the treatment of non-clear cell renal cancer, as presented at ASCO. Discover how the combination of lenvatinib and pembrolizumab is setting new standards for patient care, showing promising results beyond its established success in endometrial and clear cell renal cancers. 👇 View all WND GU videos - link in the comments! #MediMix #GUCancer #RenalCancer #OncologyInnovation